SUZHOU, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- CMAB Biopharma Inc. (CMAB), a full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products, announces that it has completed series A financing of US$38 million led by C-Bridge Capital and BioBAY, with I-Bridge Capital and Qianhai FoF fund joining the consortium.

CMAB, located in the BioBAY Park, Suzhou, will provide services for development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products. Initial services will generate pre-clinical and early-stage clinical (Phase I/II) products for Chinese and global clients. CMAB’s manufacturing follows global Good Manufacturing Practices (GMP) standards, including those of the China Food & Drug Administration, US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards. Currently, CMAB has 65 employees and plans to expand to 180 staff within one year.

“Our experienced team is CMAB’s biggest asset,” according to President Mr. Liang Qibin. “The CMAB management team has extensive experience gained from international biopharmaceutical companies and has collectively delivered more than 100 CDMO projects, resulting in at least 40 IND applications for biological drugs. Our goal is to provide quality services and become the preferred trusted partner for our clients.” 

Meng Jiang, Managing Director of C-Bridge added, “With the regulatory advancement of MAH in China, we believe there is urgent need for high quality pure-play CDMO services. CMAB’s commitment to global quality standards is aligned with rising regulatory standards and the ultimate goal of bringing higher quality products to patients domestically and around the world.”   

About CMAB:
CMAB is a flexible full-service CDMO dedicated to providing bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Our adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow’s medicines from DNA to clinical product today.
To find out more about our dynamic new CMO, please go to the website:

About C-Bridge:
C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities with US$800 million of Assets Under Management. C-Bridge Capital’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital is committed to support commercialization of cutting edge technologies and companies that fulfill unmet medical needs, thus continuously improving the standard and quality of care for patients. Learn more at

About BioBAY:
Located in the southwest of Suzhou Industrial Park, BioBAY has established itself as a pivotal role in life science innovation, clustering more than 460 high-tech startups covering the fields of drug discovery, medical devices and diagnosis, biotechnology, and nanotechnology.  With the cooperation of Cold Spring Harbor Asia, BioBAY has further evolved into a global community attracting more than 10,000 Life Scientists and Entrepreneurs to meet, exchange ideas, and work closely in a dynamic and vibrant environment.


Tel: (86) 0512-69566088
Address: Bld. C37, No. 188 Dong Ping Road, Su Zhou Industry Campus
CMAB BioPharma (Su Zhou) Inc.

James Cen Bonsor
Investor Relations Director
C-Bridge Capital
+86 186 1687 3122

In the U.S.
James Heins
Senior Vice President
ICR Healthcare
(203) 856-2121

In China:
Edmond Lococo
Senior Vice President
ICR Asia
Phone: (86) 10 6583 7510